The Advanced Health Technologies (NATS) Division brings together scientific and technical competencies with groups specialized in proteomics, gene editing, tissue engineering, immunotherapy and biologicals. Its central mission is to meet the demands of research, development and innovation (RD&I) in health, translating basic science knowledge to strengthen the health economic and industrial complex and Brazil’s public health system (Sistema Único de Saúde, also known as SUS). The division plays a fundamental role in carrying out activities that foster transformation of basic scientific knowledge into technological solutions to benefit the Brazilian population.
Its main deliverables include generation of cell lines producing monoclonal antibodies, development of CRISPR-based platforms to treat genetic diseases, creating alternative models capable of testing biological systems in vitro, developing biodressings and developing proteomic methods to identify and validate molecular signatures with diagnostic and prognostic value for use in precision medicine. These initiatives drive competitiveness, technological sovereignty and the sustainability of the domestic health sector.
This center is dedicated to establishing gene therapy strategies using CRISPR/Cas9, base editing and prime editing to treat diseases that still do not have cures. The team has also been working to optimize encapsulation and delivery of these advanced therapy products (ATP) to develop safer and more effective treatments
Formulation of innovative therapeutic strategies based on viral vectors, nanoparticles, chimeric aptamers and monoclonal antibodies. This group has expertise in the production of vectors derived from retroviruses, lentiviruses, adenoviruses and adeno-associated viruses, and can also generate cell banks that produce human monoclonal antibodies, known as research cell banks (RCB)
This center develops mass spectrometry proteomics methods to identify and quantify proteins and peptides, including spatial, structural, single-cell and computational proteomics. The work focuses on discovery and validation of molecular signatures with diagnostic, prognostic and therapeutic potential that are aligned with precision medicine and health innovation
This center uses innovative biomaterial formulations and bioprinting technologies to develop 3D cell models. It focuses on creation of in vitro models as alternatives to animal testing and on progress in advanced therapies, with emphasis on the development of biodressings
Expanding the understanding of diseases, identifying molecular targets for personalized therapies, and translating discoveries into health benefits
Implementing methods for scientific results on the cutting-edge of knowledge, playing a vital role in developing and new experimental approaches and putting them into action
Expanding our understanding of the mechanisms of viral and bacterial illnesses and those that affect neglected populations, such as Chagas disease
Enables radical innovation in pharmaceuticals in Brazil through the sustainable use of biodiversity in connection with cutting-edge science and high technology